After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI
WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute (NCI) for the past 5 years, says that he will resign his post in April of this year. He will join IVAX Corporation (Miami), a manufacturer of generic drugs and IV drug delivery devices, where he plans to work on developing new drugs.
WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute(NCI) for the past 5 years, says that he will resign his postin April of this year. He will join IVAX Corporation (Miami),a manufacturer of generic drugs and IV drug delivery devices,where he plans to work on developing new drugs.
Dr. Broder first joined the NCI in 1972 as a researcher. He wasthe leader of a group that discovered the therapeutic benefitsof the antiretroviral agent zidovudine (Retrovir, AZT) in 1985.
Gathering the Latest Multidisciplinary Care Insights Across World GU 2025
Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.
Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling
Enhancing patient adherence to follow-up care for leukoplakia through habit cessation counseling and patient information leaflets may reduce oral cancer risks.
